Comparison results
| Results: Differences General | ✘B37 | ✘H48 | ||||||||||
| Related research | Analogs | Analogs | ||||||||||
| ||||||||||||
| Distinctive symptoms | ||||||||||||
| Register, to see more distinctive signs of diseases and studies | 100% | — | ||||||||||
| Register, to see more distinctive signs of diseases and studies | — | 100% | ||||||||||
| candidiasis of the oral cavity | 96% | — | ||||||||||
| optic neuritis | — | 57% | ||||||||||
| thrush in the mouth | 91% | — | ||||||||||
| neuritis | — | 57% | ||||||||||
| candida balanitis | 82% | — | ||||||||||
| neuralgia | — | 56% | ||||||||||
| oropharyngeal candidiasis | 77% | — | ||||||||||
| neurological disorders | — | 46% | ||||||||||
| fungus | 73% | — | ||||||||||
| not classified in other categories | — | 44% | ||||||||||
| systemic candidiasis | 72% | — | ||||||||||
| scotoma | — | 36% | ||||||||||
| superficial candidiasis | 68% | — | ||||||||||
| narrowing of the fields of vision | — | 34% | ||||||||||
| candidiasis of the lungs | 68% | — | ||||||||||
| loss of visual fields | — | 34% | ||||||||||
| balanoposthitis in boys | 64% | — | ||||||||||
| multiple sclerosis | — | 32% | ||||||||||
| purulent discharge from the urethra | 61% | — | ||||||||||
| consequences of a viral infection | — | 31% | ||||||||||
| invasive candidiasis | 60% | — | ||||||||||
| adaptation disorders | — | 30% | ||||||||||
| ulcers on | 60% | — | ||||||||||
| overexcitation of the psyche | — | 29% | ||||||||||
| aphthae on the tongue | 60% | — | ||||||||||
| inflammation of the eyes | — | 28% | ||||||||||
| throat sensitive | 59% | — | ||||||||||
| illness from stress | — | 27% | ||||||||||
| tongue atrophy | 59% | — | ||||||||||
| leukoencephalitis | — | 26% | ||||||||||
| candida fungi | 57% | — | ||||||||||
| serious condition | — | 26% | ||||||||||
| aphthous stomatitis | 49% | — | ||||||||||
| aggressive | — | 25% | ||||||||||
| lower respiratory tract infections | 46% | — | ||||||||||
| visual impairment | — | 25% | ||||||||||
| type 1 diabetes mellitus | 45% | — | ||||||||||
| zpr fatigue from the disease | — | 25% | ||||||||||
| ARVI | 42% | — | ||||||||||
| emotional | — | 23% | ||||||||||
| hiv | 40% | — | ||||||||||
| damage to the nervous system | — | 22% | ||||||||||
| bacteremia | 39% | — | ||||||||||
| consequences of infection | — | 22% | ||||||||||
| sepsis | 38% | — | ||||||||||
| onset of illness | — | 22% | ||||||||||
| diabetes mellitus | 37% | — | ||||||||||
| drug disease | — | 22% | ||||||||||
| impaired lung function | 34% | — | ||||||||||
| consequences of taking medications | — | 21% | ||||||||||
| blood diseases | 33% | — | ||||||||||
| history of surgery | — | 20% | ||||||||||
| patient's condition | 45% | 20% | ||||||||||
| inflammation | 31% | 41% | ||||||||||
| weakening of immunity | 42% | 27% | ||||||||||
| immunodeficiency | 38% | 24% | ||||||||||
Instructions
Video 
|
